Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Shares Shorted: Short Interest Down 60.8% in September

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the target of a significant drop in short interest during the month of September. As of September 30th, there was short interest totaling 13,598 shares, a drop of 60.8% from the September 15th total of 34,666 shares. Based on an average daily trading volume, of 32,535 shares, the days-to-cover ratio is currently 0.4 days. Currently, 1.0% of the shares of the company are sold short.

Aspire Biopharma Price Performance

Shares of NASDAQ:ASBP opened at $8.10 on Thursday. The company has a market cap of $11.34 million, a price-to-earnings ratio of -0.12 and a beta of 0.17. Aspire Biopharma has a one year low of $3.31 and a one year high of $562.92. The firm has a fifty day moving average price of $8.33 and a two-hundred day moving average price of $9.36.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Aspire Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 25th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Aspire Biopharma presently has an average rating of “Sell”.

Aspire Biopharma Company Profile

Aspire Biopharma, Inc is a biotechnology company focused on developing rapid drug-delivery technologies and pharmaceutical products. The company’s platform is designed to administer medications through the sublingual and buccal tissues of the mouth, with the goal of enabling faster absorption than conventional oral tablets.

Aspire Biopharma’s lead product candidate is an orally delivered, fast-acting aspirin formulation intended for potential use in cardiovascular emergencies and other situations in which rapid aspirin administration may be beneficial.